Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 3.7% - Should You Sell?

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) were down 3.7% on Friday . The stock traded as low as $3.64 and last traded at $3.64. Approximately 87,011 shares traded hands during trading, a decline of 95% from the average daily volume of 1,889,799 shares. The stock had previously closed at $3.78.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Ironwood Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $10.40.

Ironwood Pharmaceuticals Stock Down 3.2 %

The company's fifty day moving average is $3.96 and its 200 day moving average is $4.65. The stock has a market cap of $585.71 million, a PE ratio of -122.00 and a beta of 0.34.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $91.60 million during the quarter, compared to analysts' expectations of $91.22 million. During the same quarter in the previous year, the business posted $0.12 EPS. The company's quarterly revenue was down 19.4% on a year-over-year basis. Equities analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current year.

Insider Activity

In other news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares in the company, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 12.90% of the company's stock.

Institutional Trading of Ironwood Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. KBC Group NV raised its stake in shares of Ironwood Pharmaceuticals by 59.3% during the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 3,198 shares during the period. Wolverine Trading LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the third quarter worth approximately $51,000. Diversified Trust Co acquired a new stake in shares of Ironwood Pharmaceuticals during the third quarter worth approximately $52,000. SG Americas Securities LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $53,000. Finally, Legacy Capital Group California Inc. acquired a new stake in shares of Ironwood Pharmaceuticals during the third quarter worth approximately $59,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.